Influence of Nutritional Intervention on Children with Type 1 Diabetes Mellitus and DPP-4 in Serum

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2017 Aug 8

PMID 28781616

Authors

Yan-Jun Dong

Li-Juan Liu

Hui-Ming Chen

Jing Sun

Ming-Hua Xiao

Jin-Hui Wu

Affiliations

Soon will be listed here.

Abstract

The level of dipeptidyl peptidase-4 (DPP-4) of children with type 1 diabetes mellitus (T1DM) was observed to evaluate the improvement in function of the nutritional intervention. In total, 132 children with T1DM (T1DM group) and 132 healthy children (NC group) based on physical examination admitted to our hospital from September 2014 to June 2015 and were studied. General data of the two groups as well as the concentration of DPP-4 and various biochemical criterion in peripheral serum were collected and analyzed. Compared with NC group, DPP-4 level of T1DM group was obviously increased (P<0.05); after insulin treatment, the serum level of DPP-4 of T1DM group decreased, but was still significantly higher than that of NC group (P<0.05). After 3 months of clinical nutritional intervention, body mass index (BMI) of children with T1DM was significantly reduced compared with data before the treatment (P<0.05). However, the level of DPP-4 appeared unchanged (P>0.05). Pearson's correlation analysis showed that the level of DPP-4 had a positive correlation with diabetic duration, BMI and gamma (γ)-glutamyl transpeptidase for children suffering TIDM (P<0.05). Multiple linear regression analysis showed that BMI may be a factor influencing DPP-4 level in serum of T1DM children. In conclusion, the level of DPP-4 in serum increased, and insulin treatment was able to decrease DPP-4 level in T1DM children. However, clinical nutritional intervention could not improve the level of DPP-4 and BMI may be an influental factor of the DPP-4 level.

References

Horowitz M, Wu T, Deane A, Jones K, Rayner C . DPP-4 Inhibition and the Known Unknown. Diabetes. 2016; 65(8):2124-6. DOI: 10.2337/dbi16-0023. View

Hallford P, St Clair D, Halley L, Mustard C, Wei J . A study of type-1 diabetes associated autoantibodies in schizophrenia. Schizophr Res. 2016; 176(2-3):186-190. DOI: 10.1016/j.schres.2016.07.020. View

Kim C, Karvonen-Gutierrez C, Kong S, Arends V, Steffes M, McConnell D . Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study. Fertil Steril. 2016; 106(6):1446-1452. PMC: 5159208. DOI: 10.1016/j.fertnstert.2016.07.009. View

Tully C, Aronow L, Mackey E, Streisand R . Physical Activity in Youth With Type 1 Diabetes: a Review. Curr Diab Rep. 2016; 16(9):85. DOI: 10.1007/s11892-016-0779-6. View

Nasir H, Narasimhan S . Type 1 diabetes: the need for culture-appropriate nutritional information for carbohydrate counting. Lancet Diabetes Endocrinol. 2016; 4(10):812. DOI: 10.1016/S2213-8587(16)30101-2. View

Mannucci E, Mosenzon O, Avogaro A . Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis. Diabetes Care. 2016; 39 Suppl 2:S196-204. DOI: 10.2337/dcS15-3024. View

Katsuyama H, Fukunaga T, Hamasaki H, Adachi H, Moriyama S, Kawaguchi A . The Influences of Withdrawal and Daily Dose Reduction of Pioglitazone on Metabolic Parameters in Patients With Type 2 Diabetes: A Retrospective Longitudinal Observational Study. J Clin Med Res. 2016; 8(8):585-90. PMC: 4931804. DOI: 10.14740/jocmr2611w. View

Itou M, Kawaguchi T, Taniguchi E, Sata M . Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol. 2013; 19(15):2298-306. PMC: 3631980. DOI: 10.3748/wjg.v19.i15.2298. View

Osawa S, Kawamori D, Katakami N, Takahara M, Sakamoto F, Katsura T . Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes. Diabetes Res Clin Pract. 2016; 113:135-42. DOI: 10.1016/j.diabres.2015.12.022. View

10.

Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens D . Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011; 60(7):1917-25. PMC: 3121429. DOI: 10.2337/db10-1707. View

11.

Kamiya H . A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease. Hemodial Int. 2016; 21(1):72-83. DOI: 10.1111/hdi.12438. View

12.

Barry A, Turgeon R . DPP-4 Inhibitors: The Seinfeld of Oral Antihyperglycemics. Can J Hosp Pharm. 2016; 69(3):253-4. PMC: 4924948. DOI: 10.4212/cjhp.v69i3.1564. View

13.

Scheen A . DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol. 2016; 12(12):1407-1417. DOI: 10.1080/17425255.2016.1215427. View

14.

Takashima S, Fujita H, Fujishima H, Shimizu T, Sato T, Morii T . Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int. 2016; 90(4):783-96. DOI: 10.1016/j.kint.2016.06.012. View

15.

Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y . Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr. 2016; 8:45. PMC: 4960737. DOI: 10.1186/s13098-016-0169-x. View

16.

Chen C, Yu Q, Zhang S, Yang P, Wang C . Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis. Int J Clin Exp Pathol. 2016; 8(11):14141-50. PMC: 4713513. View

17.

Karagiannis T, Paschos P, Paletas K, Matthews D, Tsapas A . Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012; 344:e1369. DOI: 10.1136/bmj.e1369. View

18.

Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S . Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol. 2013; 12:125. PMC: 3765742. DOI: 10.1186/1475-2840-12-125. View

19.

Li S, Xu H, Cui S, Wu F, Zhang Y, Su M . Discovery and Rational Design of Natural-Product-Derived 2-Phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes. J Med Chem. 2016; 59(14):6772-90. DOI: 10.1021/acs.jmedchem.6b00505. View

20.

Schnapp G, Klein T, Hoevels Y, Bakker R, Nar H . Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure. J Med Chem. 2016; 59(16):7466-77. DOI: 10.1021/acs.jmedchem.6b00475. View